FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1011-1018 April 18, 1996 Number 16 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In patients with human immunodeficiency virus (HIV) infection, combined treatment with several agents may increase the effectiveness of antiviral therapy. We studied the safety and efficacy of saquinavir, an HIV-protease inhibitor, given with one or two nucleoside antiretroviral agents, as compared with the safety and efficacy of a combination of two nucleosides alone.

Methods In this double-blind trial, patients with HIV infection were randomly assigned to receive either saquinavir (1800 mg per day) plus both zidovudine (600 mg per day) and zalcitabine (2.25 mg per day) or zidovudine plus either saquinavir or zalcitabine. The 302 patients enrolled had CD4+ counts of 50 to 300 cells per cubic millimeter and had previously received zidovudine for a median of 27 months. The study lasted 24 weeks, with an optional double-blind extension period of an additional 12 to 32 weeks.

Results Ninety-six percent of the patients completed the 24-week study. In all three treatment groups, CD4+ cell counts rose at first and then fell gradually. The normalized area under the curve for the CD4+ cell count was greater with the three-drug combination than with either saquinavir and zidovudine (P = 0.017) or zalcitabine and zidovudine (P<0.001). There were significantly greater reductions in plasma HIV with the three-drug combination than with the other regimens when peripheral-blood mononuclear cells were cultured for HIV and HIV RNA was assessed, and there were greater decreases in serum neopterin and beta₂-microglobulin levels. There were no major differences in toxic effects among the three treatments.

Conclusions Treatment with saquinavir, zalcitabine, and zidovudine was well tolerated. This drug combination reduced HIV-1 replication, increased CD4+ cell counts, and decreased levels of activation markers in serum more than did treatment with zidovudine and either saquinavir or zalcitabine. Studies are warranted to evaluate whether the three-drug combination will reduce morbidity and mortality.

Source Information

From the University of Washington School of Medicine, Seattle (A.C.C., R.W.C., C.H., L.C.); the Harvard School of Public Health, Boston (D.A.S., R.L.B.); the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (J.T.); Hoffmann–LaRoche, Nutley, N.J. (A.B.); Roche Products, Welwyn Garden City, United Kingdom (M.J., K.F.); Ohio State University, Columbus (C.W.); New York University, New York (V.J.M.); the University of Pennsylvania, Philadelphia (H.M.F.); Stanford University, Palo Alto, Calif. (T.C.M.); and the University of Rochester, Rochester, N.Y. (R.C.R.).

Address reprint requests to Dr. Collier at 1001 Broadway, Suite 218, Seattle, WA 98122.

Full Text of this Article

This article has been cited by other articles:

• Jimenez-Nacher, I., Garcia, B., Barreiro, P., Rodriguez-Novoa, S., Morello, J., Gonzalez-Lahoz, J., de Mendoza, C., Soriano, V. (2008). Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 0: dkn252v1-7 [Abstract] [Full Text]  
• Marin-Niebla, A., Lopez-Cortes, L. F., Ruiz-Valderas, R., Viciana, P., Mata, R., Gutierrez, A., Pascual, R., Rodriguez, M. (2007). Clinical and Pharmacokinetic Data Support Once-Daily Low-Dose Boosted Saquinavir (1,200 Milligrams Saquinavir with 100 Milligrams Ritonavir) in Treatment-Naive or Limited Protease Inhibitor-Experienced Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 51: 2035-2042 [Abstract] [Full Text]  
• Ylitalo, N., Brogly, S., Hughes, M. D., Nachman, S., Dankner, W., Van Dyke, R., Seage, G. R. III, for the Pediatric AIDS Clinical Trials Group Proto, (2006). Risk Factors for Opportunistic Illnesses in Children With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy. Arch Pediatr Adolesc Med 160: 778-787 [Abstract] [Full Text]  
• Dewan, M. Z., Uchihara, J.-n., Terashima, K., Honda, M., Sata, T., Ito, M., Fujii, N., Uozumi, K., Tsukasaki, K., Tomonaga, M., Kubuki, Y., Okayama, A., Toi, M., Mori, N., Yamamoto, N. (2006). Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 107: 716-724 [Abstract] [Full Text]  
• Brogly, S., Williams, P., Seage, G. R. III, Oleske, J. M., Van Dyke, R., McIntosh, K., for the PACTG 219C Team, (2005). Antiretroviral Treatment in Pediatric HIV Infection in the United States: From Clinical Trials to Clinical Practice. JAMA 293: 2213-2220 [Abstract] [Full Text]  
• Equils, O., Shapiro, A., Madak, Z., Liu, C., Lu, D. (2004). Human Immunodeficiency Virus Type 1 Protease Inhibitors Block Toll-Like Receptor 2 (TLR2)- and TLR4-Induced NF-{kappa}B Activation. Antimicrob. Agents Chemother. 48: 3905-3911 [Abstract] [Full Text]  
• Huitron-Resendiz, S., de Rozieres, S., Sanchez-Alavez, M., Buhler, B., Lin, Y.-C., Lerner, D. L., Henriksen, N. W., Burudi, M., Fox, H. S., Torbett, B. E., Henriksen, S., Elder, J. H. (2004). Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3. J. Virol. 78: 4525-4532 [Abstract] [Full Text]  
• Kim, H., Yin, J. (2004). Quantitative Analysis of a Parasitic Antiviral Strategy. Antimicrob. Agents Chemother. 48: 1017-1020 [Abstract] [Full Text]  
• Yazdanpanah, Y., Sissoko, D., Egger, M., Mouton, Y., Zwahlen, M., Chene, G. (2004). Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 328: 249- [Abstract] [Full Text]  
• Zeldin, R. K., Petruschke, R. A. (2004). Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53: 4-9 [Abstract] [Full Text]  
• Chen, H., Pai, S. B., Hurwitz, S. J., Chu, C. K., Glazkova, Y., McClure, H. M., Feitelson, M., Schinazi, R. F. (2003). Antiviral Activity and Pharmacokinetics of 1-(2,3-Dideoxy-2-Fluoro-{beta}-L-Glyceropent-2-Enofuranosyl)Cytosine. Antimicrob. Agents Chemother. 47: 1922-1928 [Abstract] [Full Text]  
• Giuffre, A. C., Higgins, J., Buckheit, R. W. Jr., North, T. W. (2003). Susceptibilities of Simian Immunodeficiency Virus to Protease Inhibitors. Antimicrob. Agents Chemother. 47: 1756-1759 [Abstract] [Full Text]  
• Reinke, R., Lee, D. J., Robinson, W. E. Jr. (2002). Inhibition of Human Immunodeficiency Virus Type 1 Isolates by the Integrase Inhibitor L-731,988, a Diketo Acid. Antimicrob. Agents Chemother. 46: 3301-3303 [Abstract] [Full Text]  
• Taggart, S., Breen, R., Goldsack, N., Sabin, C., Johnson, M., Lipman, M. (2002). The Changing Pattern of Bronchoscopy in an HIV-Infected Population*. Chest 122: 878-885 [Abstract] [Full Text]  
• Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S. Jr, Weichold, F. F. (2002). Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99: 3771-3779 [Abstract] [Full Text]  
• Estaquier, J., Lelievre, J.-D., Petit, F., Brunner, T., Moutouh-de Parseval, L., Richman, D. D., Ameisen, J. C., Corbeil, J. (2002). Effects of Antiretroviral Drugs on Human Immunodeficiency Virus Type 1-Induced CD4+ T-Cell Death. J. Virol. 76: 5966-5973 [Abstract] [Full Text]  
• Besson, C., Goubar, A., Gabarre, J., Rozenbaum, W., Pialoux, G., Chatelet, F.-P., Katlama, C., Charlotte, F., Dupont, B., Brousse, N., Huerre, M., Mikol, J., Camparo, P., Mokhtari, K., Tulliez, M., Salmon-Ceron, D., Boue, F., Costagliola, D., Raphael, M. (2001). Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98: 2339-2344 [Abstract] [Full Text]  
• Lu, W., Andrieu, J.-M. (2001). In Vitro Human Immunodeficiency Virus Eradication by Autologous CD8+ T Cells Expanded with Inactivated-Virus-Pulsed Dendritic Cells. J. Virol. 75: 8949-8956 [Abstract] [Full Text]  
• Kahn, J. G., Haile, B., Kates, J., Chang, S. (2001). Health and Federal Budgetary Effects of Increasing Access to Antiretroviral Medications for HIV by Expanding Medicaid. Am. J. Public Health 91: 1464-1473 [Abstract] [Full Text]  
• Lu, W., Achour, A., Arlie, M., Cao, L., Andrieu, J.-M. (2001). Enhanced Dendritic Cell-Driven Proliferation and Anti-HIV Activity of CD8+ T Cells by a New Phenothiazine Derivative, Aminoperazine. J. Immunol. 167: 2929-2935 [Abstract] [Full Text]  
• Phenix, B. N., Lum, J. J., Nie, Z., Sanchez-Dardon, J., Badley, A. D. (2001). Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98: 1078-1085 [Abstract] [Full Text]  
• Sakurai, E., Matsuda, Y., Ozeki, H., Kunou, N., Nakajima, K., Ogura, Y. (2001). Scleral Plug of Biodegradable Polymers Containing Ganciclovir for Experimental Cytomegalovirus Retinitis. IOVS 42: 2043-2048 [Abstract] [Full Text]  
• Mittler, J., Essunger, P., Yuen, G. J., Clendeninn, N., Markowitz, M., Perelson, A. S. (2001). Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy. Antimicrob. Agents Chemother. 45: 1438-1443 [Abstract] [Full Text]  
• Binquet, C., Chene, G., Jacqmin-Gadda, H., Journot, V., Saves, M., Lacoste, D., Dabis, F., and the Groupe d'Epidémiologie Clinique du, (2001). Modeling Changes in CD4-positive T-Lymphocyte Counts after the Start of Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections The Aquitaine Cohort, 1996-1997. Am J Epidemiol 153: 386-393 [Abstract] [Full Text]  
• Gilbert, P. B., DeGruttola, V., Hammer, S. M., Kuritzkes, D. R. (2001). Virologic and Regimen Termination Surrogate End Points in AIDS Clinical Trials. JAMA 285: 777-784 [Abstract] [Full Text]  
• Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C. (2001). Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy. J. Clin. Microbiol. 39: 454-459 [Abstract] [Full Text]  
• Savès, M., Raffi, F., Clevenbergh, P., Marchou, B., Waldner-Combernoux, A., Morlat, P., Le Moing, V., Rivière, C., Chêne, G., Leport, C., The APROCO Study Group, (2000). Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 44: 3451-3455 [Abstract] [Full Text]  
• Eugenio, K. R., Zeind, C. S. (2000). Management of HIV-1 Infection in Adults and Adolescents. Journal of Pharmacy Practice 13: 426-441 [Abstract]  
• Badley, A. D., Pilon, A. A., Landay, A., Lynch, D. H. (2000). Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96: 2951-2964 [Abstract] [Full Text]  
• Amirayan-Chevillard, N., Tissot-Dupont, H., Obadia, Y., Gallais, H., Mege, J.-L., Capo, C. (2000). Highly Active Antiretroviral Therapy (HAART) and Circulating Markers of Immune Activation: Specific Effect of HAART on Neopterin. CVI 7: 832-834 [Abstract] [Full Text]  
• Washington, C. B., Wiltshire, H. R., Man, M., Moy, T., Harris, S. R., Worth, E., Weigl, P., Liang, Z., Hall, D., Marriott, L., Blaschke, T. F. (2000). The Disposition of Saquinavir in Normal and P-glycoprotein Deficient Mice, Rats, and in Cultured Cells. Drug Metab. Dispos. 28: 1058-1062 [Abstract] [Full Text]  
• Brodie, S. J. (2000). Nonlymphoid reservoirs of HIV replication in children with chronic-progressive disease. J. Leukoc. Biol. 68: 351-359 [Abstract] [Full Text]  
• Lu, W., Andrieu, J.-M. (2000). HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 96: 250-258 [Abstract] [Full Text]  
• Sei, S., Yang, Q.-e., O'Neill, D., Yoshimura, K., Nagashima, K., Mitsuya, H. (2000). Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within the gag-pol Transframe Domain. J. Virol. 74: 4621-4633 [Abstract] [Full Text]  
• Erb, P., Battegay, M., Zimmerli, W., Rickenbach, M., Egger, M., for the Swiss HIV Cohort Study, (2000). Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus-Infected Cohort. Arch Intern Med 160: 1134-1140 [Abstract] [Full Text]  
• Aboulafia, D. M. (2000). The Epidemiologic, Pathologic, and Clinical Features of AIDS-Associated Pulmonary Kaposi’s Sarcoma. Chest 117: 1128-1145 [Abstract] [Full Text]  
• Nickas, G., Wachter, R. M. (2000). Outcomes of Intensive Care for Patients With Human Immunodeficiency Virus Infection. Arch Intern Med 160: 541-547 [Abstract] [Full Text]  
• Sulkowski, M. S., Thomas, D. L., Chaisson, R. E., Moore, R. D. (2000). Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. JAMA 283: 74-80 [Abstract] [Full Text]  
• Campbell, T. B., Sevin, A., Coombs, R. W., Peterson, G. C., Rosandich, M., Kuritzkes, D. R., Mladenovic, J., Landay, A., Wong, R., Ambruso, D., Miles, S., Pomerantz, R. J., Schooley, R. T., the Adult AIDS Clinical Trials Group 285 Study Tea, (2000). Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Blood 95: 48-55 [Abstract] [Full Text]  
• Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., Ruiz, N. M., The Study 006 Team, (1999). Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. NEJM 341: 1865-1873 [Abstract] [Full Text]  
• Moyer, T. P., Temesgen, Z., Enger, R., Estes, L., Charlson, J., Oliver, L., Wright, A. (1999). Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study. Clin. Chem. 45: 1465-1476 [Abstract] [Full Text]  
• Valdez, H., Lederman, M. M., Woolley, I., Walker, C. J., Vernon, L. T., Hise, A., Gripshover, B. M. (1999). Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice: Predictors of Virological Outcome. Arch Intern Med 159: 1771-1776 [Abstract] [Full Text]  
• Martin, D. F., Kuppermann, B. D., Wolitz, R. A., Palestine, A. G., Li, H., Robinson, C. A., The Roche Ganciclovir Study Group, (1999). Oral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir Implant. NEJM 340: 1063-1070 [Abstract] [Full Text]  
• Boden, D., Markowitz, M. (1998). Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 42: 2775-2783 [Full Text]  
• Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J.-A., Dellamonica, P., Yeni, P., Delfraissy, J.-F., Aboulker, J.-P., The Trilege (Agence Nationale de Recherches sur le, (1998). A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1-Infected Patients. NEJM 339: 1269-1276 [Abstract] [Full Text]  
• Patick, A. K., Potts, K. E. (1998). Protease Inhibitors as Antiviral Agents. Clin. Microbiol. Rev. 11: 614-627 [Abstract] [Full Text]  
• Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M. R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D. R., Markowitz, M. (1998). Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir. Antimicrob. Agents Chemother. 42: 2637-2644 [Abstract] [Full Text]  
• King, P. J., Robinson, W. E. Jr. (1998). Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compound L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase. J. Virol. 72: 8420-8424 [Abstract] [Full Text]  
• (1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics 102: 1005-1062 [Full Text]  
• David, D., Bani, L., Moreau, J.-L., Treilhou, M.-P., Nakarai, T., Joussemet, M., Ritz, J., Dupont, B., Pialoux, G., Theze, J. (1998). Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc. Natl. Acad. Sci. USA 95: 11348-11353 [Abstract] [Full Text]  
• Fayz, S., Inaba, T. (1998). Zidovudine Azido-Reductase in Human Liver Microsomes: Activation by Ethacrynic Acid, Dipyridamole, and Indomethacin and Inhibition by Human Immunodeficiency Virus Protease Inhibitors. Antimicrob. Agents Chemother. 42: 1654-1658 [Abstract] [Full Text]  
• Dutschman, G. E., Bridges, E. G., Liu, S.-H., Gullen, E., Guo, X., Kukhanova, M., Cheng, Y.-C. (1998). Metabolism of 2',3'-Dideoxy-2',3'-Didehydro-beta -L(-)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus beta -D(+) Nucleoside Analogs In Vitro. Antimicrob. Agents Chemother. 42: 1799-1804 [Abstract] [Full Text]  
• WHITCUP, S. M, JR, E. T C., POLIS, M. A, FORTIN, E. (1998). Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy. Br. J. Ophthalmol. 82: 841f-841 [Full Text]  
• Chan, K. S., Revicki, D. A. (1998). Changes in Surrogate Laboratory Markers, Clinical Endpoints, and Health-Related Quality of Life in Patients Infected with the Human Immunodeficiency Virus. Eval Health Prof 21: 265-281 [Abstract]  
• Gordon, F H, Mistry, P K, Sabin, C A, Lee, C A (1998). Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 42: 744-749 [Abstract] [Full Text]  
• Tenner-Racz, K., Stellbrink, H.-J., van Lunzen, J., Schneider, C., Jacobs, J.-P., Raschdorff, B., Grossschupff, G., Steinman, R. M., Racz, P. (1998). The Unenlarged Lymph Nodes of HIV-1-infected, Asymptomatic Patients with High CD4 T Cell Counts Are Sites for Virus Replication and CD4 T Cell Proliferation. The Impact of Highly Active Antiretroviral Therapy. J. Exp. Med. 187: 949-959 [Abstract] [Full Text]  
• Mueller, B. U., Nelson Jr, R. P., Sleasman, J., Zuckerman, J., Heath-Chiozzi, M., Steinberg, S. M., Balis, F. M., Brouwers, P., Hsu, A., Saulis, R., Sei, S., Wood, L. V., Zeichner, S., Katz, T. T. K., Higham, C., Aker, D., Edgerly, M., Jarosinski, P., Serchuck, L., Whitcup, S. M., Pizzuti, D., Pizzo, P. A. (1998). A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection. Pediatrics 101: 335-343 [Abstract] [Full Text]  
• Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G. (1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA 279: 450-454 [Abstract] [Full Text]  
• Stout, J. C., Ellis, R. J., Jernigan, T. L., Archibald, S. L., Abramson, I., Wolfson, T., McCutchan, J. A., Wallace, M. R., Atkinson, J. H., Grant, I., and the HIV Neurobehavioral Research Center Group, (1998). Progressive Cerebral Volume Loss in Human Immunodeficiency Virus Infection: A Longitudinal Volumetric Magnetic Resonance Imaging Study. Arch Neurol 55: 161-168 [Abstract] [Full Text]  
• McDougall, B., King, P. J., Wu, B. W., Hostomsky, Z., Reinecke, M. G., Robinson, W. E. Jr. (1998). Dicaffeoylquinic and Dicaffeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase. Antimicrob. Agents Chemother. 42: 140-146 [Abstract] [Full Text]  
• Gostin, L. O., Ward, J. W., Baker, A. C. (1997). National HIV Case Reporting for the United States -- A Defining Moment in the History of the Epidemic. NEJM 337: 1162-1167 [Full Text]  
• Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., Chodakewitz, J. A., Deutsch, P., Holder, D., Schleif, W. A., Condra, J. H. (1997). Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. NEJM 337: 734-739 [Abstract] [Full Text]  
• Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., Leibowitch, J. (1997). Positive Effects of Combined Antiretroviral Therapy on CD4⁺ T Cell Homeostasis and Function in Advanced HIV Disease. Science 277: 112-116 [Abstract] [Full Text]  
• Englund, J. A., Baker, C. J., Raskino, C., McKinney, R. E., Petrie, B., Fowler, M. G., Pearson, D., Gershon, A., McSherry, G. D., Abrams, E. J., Schliozberg, J., Sullivan, J. L., Behrman, R., Connor, J. C., Hetherington, S., Lifschitz, M. H., McLaren, C., Mendez, H., Millison, K., Moye, J., Nozyce, M., O'Donnell, K., Purdue, L., Schoenfeld, D., Scott, G., Spector, S. A., Wara, D. W., The AIDS Clinical Trials Group (ACTG) Study 152 Te, (1997). Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children. NEJM 336: 1704-1712 [Abstract] [Full Text]  
• (1997). Major advances in the treatment of HIV-1 infection. DTB 35: 25-29 [Abstract] [Full Text]  
• Serio, D., Rizvi, T. A., Cartas, M., Kalyanaraman, V. S., Weber, I. T., Koprowski, H., Srinivasan, A. (1997). Development of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc. Natl. Acad. Sci. USA 94: 3346-3351 [Abstract] [Full Text]  
• Cohn, J. A. (1997). Recent advances: hiv infection–I. BMJ 314: 487-487 [Full Text]  
• Oliphant, C. M., Bonnema, S. M. (1997). New Advances in the Pharmacological Treatment of Human Immunodeficiency Virus (HIV) Infection: Focus on Protease Inhibitors. Journal of Pharmacy Practice 10: 20-51 [Abstract]  
• Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea, (1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 335: 1081-1090 [Abstract] [Full Text]  
• Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T. C., Hirsch, M. S., The AIDS Clinical Trials Group Study 175 Virology, (1996). The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter. NEJM 335: 1091-1098 [Abstract] [Full Text]  
• (1996). New Antiviral Combinations. AIDS Clin Care 1996: 7-7 [Full Text]  
• (1996). ADDING PROTEASE INHIBITORS TO ANTI-HIV TREATMENT. JWatch General 1996: 1-1 [Full Text]  
• Stranford, S. A., Ong, J. C., Martinez-Marino, B., Busch, M., Hecht, F. M., Kahn, J., Levy, J. A. (2001). Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc. Natl. Acad. Sci. USA 98: 597-602 [Abstract] [Full Text]